Comparative Pharmacology
Head-to-head clinical analysis: CORTEF ACETATE versus HYTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTEF ACETATE versus HYTONE.
CORTEF ACETATE vs HYTONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory and immunosuppressant activity; binds to glucocorticoid receptors, modulating gene expression and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
Hydrocortisone (topical) binds to glucocorticoid receptors, activating anti-inflammatory proteins and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
Adult: 5-60 mg orally every 6-12 hours (hydrocortisone base equivalent), or 10-240 mg IV/IM every 12 hours (as hydrocortisone sodium succinate). Dose depends on severity and condition.
Topical: Apply cream or ointment to affected area 2-4 times daily. Limit treatment area to less than 50% of body surface area. Maximum duration: 2 weeks unless directed by physician.
None Documented
None Documented
Plasma terminal half-life is approximately 1.5-2 hours. However, biologic half-life (duration of adrenal suppression) is 18-36 hours due to intracellular receptor binding.
30–60 minutes (terminal elimination half-life; short duration requires frequent dosing)
Primarily renal as inactive metabolites; less than 5% unchanged. Biliary/fecal elimination is minimal (<2%).
Renal (primarily as metabolites; ~25% as unchanged drug) and biliary/fecal
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid